The evolving role of PARP inhibitors in advanced ovarian cancer
, , , , , y
09 ago 2021
Acerca de este artículo
Categoría del artículo: Research Article
Publicado en línea: 09 ago 2021
Páginas: 82 - 104
Recibido: 02 ene 2021
Aceptado: 18 feb 2021
DOI: https://doi.org/10.2478/fco-2021-0002
Palabras clave
© 2021 Sofia Levva et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Levva, Sofia
Oncology Department, Bioclinic Private HospitalThessaloniki, Greece
Skolariki, Aglaia
Department of Medical Oncology, Papageorgiou General HospitalThessaloniki, Greece
Sogka, Eleni
Department of Medical Oncology, Papageorgiou General HospitalThessaloniki, Greece
Bokas, Alexandros
1st Department of Medical Oncology, Theagenion HospitalThessaloniki, Greece
Assi, Avraam
2nd Department of Medical Oncology, Henry Dunant Hospital CenterAthens, Greece
Pispirigou, Marianna K.
Division of Oncology, Department of Internal Medicine, University Hospital of PatrasGreece
Koliou, Panagiotis
Royal Surrey NHS Foundation TrustGuildford, United Kingdom